InsiderTrades.com logo
There is a little known company that is changing warfare
From Reticulate   |   Ad
With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.
Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t
Kenneth DiPietro net worth and biography
  • Phone
  • Email
  • Website

Kenneth DiPietro Biography and Net Worth

Insider of Cerevel Therapeutics

Ken DiPietro, has served as our Chief Human Resources Officer since April 2019.

Prior to joining us, Mr. DiPietro worked as the chief talent officer for Oak Hill Capital Partners and was a senior advisor to several Polaris Ventures portfolio companies. Previously, he was a director at InVivo Therapeutics Holdings Corp. after serving as executive vice president of human resources at Biogen Inc. Earlier in his career, Mr. DiPietro held senior human resources roles with Lenovo Group Limited, Microsoft Corporation and Dell Technologies. Mr. DiPietro also served in a range of human resource and general management positions over a 19-year period at PepsiCo.

Mr. DiPietro earned a B.S. in industrial and labor relations from Cornell University. He sits on the Dean’s Advisory Board at Cornell, the Peer Roundtable, and the Boston Posse Advisory Board, and advises technology start-ups focused on human resource management.

What is Kenneth DiPietro's net worth?

The estimated net worth of Kenneth DiPietro is at least $1.11 million as of December 22nd, 2023. Mr. DiPietro owns 24,663 shares of Cerevel Therapeutics stock worth more than $1,108,848 as of November 16th. This net worth approximation does not reflect any other investments that Mr. DiPietro may own. Learn More about Kenneth DiPietro's net worth.

How old is Kenneth DiPietro?

Mr. DiPietro is currently 65 years old. There are 8 older executives and no younger executives at Cerevel Therapeutics. Learn More on Kenneth DiPietro's age.

How do I contact Kenneth DiPietro?

The corporate mailing address for Mr. DiPietro and other Cerevel Therapeutics executives is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. Cerevel Therapeutics can also be reached via phone at 844-304-2048 and via email at [email protected]. Learn More on Kenneth DiPietro's contact information.

Has Kenneth DiPietro been buying or selling shares of Cerevel Therapeutics?

Kenneth DiPietro has not been actively trading shares of Cerevel Therapeutics during the past quarter. Most recently, Kenneth Dipietro sold 8,000 shares of the business's stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $41.45, for a transaction totalling $331,600.00. Following the completion of the sale, the insider now directly owns 24,663 shares of the company's stock, valued at $1,022,281.35. Learn More on Kenneth DiPietro's trading history.

Who are Cerevel Therapeutics' active insiders?

Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.

Are insiders buying or selling shares of Cerevel Therapeutics?

In the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 236,864 shares worth more than $9,768,056.92. The most recent insider tranaction occured on July, 1st when Director N Anthony Coles sold 25,000 shares worth more than $1,029,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company. Learn More about insider trades at Cerevel Therapeutics.

Information on this page was last updated on 7/1/2024.

Kenneth DiPietro Insider Trading History at Cerevel Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/22/2023Sell8,000$41.45$331,600.0024,663View SEC Filing Icon  
See Full Table

Kenneth DiPietro Buying and Selling Activity at Cerevel Therapeutics

This chart shows Kenneth Dipietro's buying and selling at Cerevel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cerevel Therapeutics Company Overview

Cerevel Therapeutics logo
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $44.96
Low: $44.96
High: $44.96

50 Day Range

MA: $43.67
Low: $40.30
High: $44.96

2 Week Range

Now: $44.96
Low: $19.59
High: $44.99

Volume

N/A

Average Volume

1,709,788 shs

Market Capitalization

$8.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4
There is a little known company that is changing warfare
From Reticulate   |   Ad
With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.
Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t